Bullish post on Intellia (NTLA) arguing the stock is undervalued and heavily shorted, with the FDA hold likely to lift after reports the trial death was unrelated to CRISPR, plus catalysts including a JPM presentation, insider/institutional buying, and 2026 milestones.
NTLA — LONG The author claims Intellia (NTLA) is an undervalued CRISPR gene-editing stock and the most heavily shorted stock, with short interest around 35-39% of float. He argues the recent trial death was from septic shock due to a perforated duodenal ulcer rather than the CRISPR treatment, so the FDA hold should lift soon and trials resume, driving a rebound. Specific catalysts cited are a JP Morgan Healthcare Conference presentation tomorrow, a $1.4 million insider purchase, continued ARK buying, and multiple 2026 milestones; these plus short positioning create squeeze potential. The main risk he discusses is the prior patient death and clinical hold, but he says it is not linked to the technology.
Since the death isn't attributed to the tech itself, the FDA hold should lift soon, trials resume, and the price ought to bounce back up.
This Reddit post, published January 13, 2026, features u/OutlandishnessSalt92 discussing NTLA. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/OutlandishnessSalt92 · Tickers: NTLA